Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.12 HKD
−405.79 M HKD
512.54 M HKD
644.36 M
About CSTONE PHARMACEUTICALS
Sector
CEO
Jian Xin Yang
Headquarters
Shanghai
Website
Founded
2015
FIGI
BBG00N9XPM92
Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. Its products include immuno-oncology drugs and molecularly targeted drugs. The company was founded on December 2, 2015, and is headquartered in Shanghai, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2616 is 2.30 HKD — it has decreased by −1.71% in the past 24 hours. Watch CSTONE PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CSTONE PHARMACEUTICALS stocks are traded under the ticker 2616.
2616 stock has fallen by −12.21% compared to the previous week, the month change is a 17.95% rise, over the last year CSTONE PHARMACEUTICALS has showed a −9.80% decrease.
2616 reached its all-time high on Jun 21, 2021 with the price of 19.12 HKD, and its all-time low was 0.80 HKD and was reached on Apr 5, 2024. View more price dynamics on 2616 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2616 stock is 6.58% volatile and has beta coefficient of 1.35. Track CSTONE PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is CSTONE PHARMACEUTICALS there?
Today CSTONE PHARMACEUTICALS has the market capitalization of 2.94 B, it has increased by 10.33% over the last week.
Yes, you can track CSTONE PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
CSTONE PHARMACEUTICALS is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
2616 earnings for the last half-year are 0.01 HKD per share, whereas the estimation was −0.11 HKD, resulting in a 110.00% surprise. The estimated earnings for the next half-year are −0.03 HKD per share. See more details about CSTONE PHARMACEUTICALS earnings.
CSTONE PHARMACEUTICALS revenue for the last half-year amounts to 273.08 M HKD, despite the estimated figure of 331.93 M HKD. In the next half-year revenue is expected to reach 335.03 M HKD.
2616 net income for the last half-year is 17.01 M HKD, while the previous report showed −170.70 M HKD of net income which accounts for 109.97% change. Track more CSTONE PHARMACEUTICALS financial stats to get the full picture.
No, 2616 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 230.00 employees. See our rating of the largest employees — is CSTONE PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CSTONE PHARMACEUTICALS EBITDA is −321.35 M HKD, and current EBITDA margin is −118.01%. See more stats in CSTONE PHARMACEUTICALS financial statements.
Like other stocks, 2616 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CSTONE PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CSTONE PHARMACEUTICALS technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CSTONE PHARMACEUTICALS stock shows the neutral signal. See more of CSTONE PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.